Deerfield Private Design Fund IV, L.P.
CIK 0001680307 Name as filed on the most recent filing
Filed as Deerfield Private Design Fund IV, L.P. (25)
65 transaction lines · from 25 filings · filed 2018-02-23 to 2026-03-02 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Larimar Therapeutics, Inc. 5 filings
- ISSUER Nuvalent, Inc. 3 filings
- ISSUER ARS Pharmaceuticals, Inc. 2 filings
- ISSUER AdaptHealth Corp. 2 filings
- ISSUER Mirum Pharmaceuticals, Inc. 4 filings
- ISSUER Singular Genomics Systems, Inc. 1 filings
- ISSUER Edgewise Therapeutics, Inc. 1 filings
- ISSUER Annexon, Inc. 1 filings
- ISSUER Nkarta, Inc. 1 filings
- ISSUER Revolution Medicines, Inc. 1 filings
- ISSUER Schrodinger, Inc. 1 filings
- ISSUER Cabaletta Bio, Inc. 1 filings
- ISSUER Frequency Therapeutics, Inc. 1 filings
- ISSUER Arvinas Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2026-02-27 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,000,000 acquired | 5.00 | 10,000,000.00 | Form 4, filing 0001193805-26-000205 | |
| 2026-02-27 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 1,084,012 acquired | 5.00 | 5,420,060.00 | Form 4, filing 0001193805-26-000205 | |
| 2026-02-27 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 1,084,010 acquired | 5.00 | 5,420,050.00 | Form 4, filing 0001193805-26-000205 | |
| 2026-02-27 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 831,978 acquired | 5.00 | 4,159,890.00 | Form 4, filing 0001193805-26-000205 | |
| 2025-11-24 |
Nuvalent, Inc. NUVL |
S, Open-market sale | 371,287 disposed | 95.44 | 35,437,487.72 | Form 4, filing 0001193805-25-001648 | |
| 2025-11-24 |
Nuvalent, Inc. NUVL |
S, Open-market sale | 371,287 disposed | 95.44 | 35,437,487.72 | Form 4, filing 0001193805-25-001648 | |
| 2025-07-31 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 3,387,539 acquired | 3.20 | 10,840,124.80 | Form 4, filing 0001193805-25-001155 | |
| 2025-07-31 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 3,387,529 acquired | 3.20 | 10,840,092.80 | Form 4, filing 0001193805-25-001155 | |
| 2025-07-31 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,599,932 acquired | 3.20 | 8,319,782.40 | Form 4, filing 0001193805-25-001155 | |
| 2025-06-27 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 370,075 disposed | 18.46 | 6,831,584.50 | Form 4, filing 0001193805-25-000959 | |
| 2025-06-27 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 370,074 disposed | 18.46 | 6,831,566.04 | Form 4, filing 0001193805-25-000959 | |
| 2024-11-12 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 9,554 disposed | 17.77 | 169,774.58 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-12 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 9,553 disposed | 17.77 | 169,756.81 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-12 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 7,854 disposed | 17.16 | 134,774.64 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-12 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 7,853 disposed | 17.16 | 134,757.48 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-11 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 223,632 disposed | 18.15 | 4,058,920.80 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-11 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 223,632 disposed | 18.15 | 4,058,920.80 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-11 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 40,596 disposed | 17.45 | 708,400.20 | Form 4, filing 0001193805-24-001348 | |
| 2024-11-11 |
ARS Pharmaceuticals, Inc. SPRY |
S, Open-market sale | 40,596 disposed | 17.45 | 708,400.20 | Form 4, filing 0001193805-24-001348 | |
| 2024-10-22 |
Nuvalent, Inc. NUVL |
S, Open-market sale | 1,000,000 disposed | 97.75 | 97,750,000.00 | Form 4, filing 0001193805-24-001275 | |
| 2024-10-22 |
Nuvalent, Inc. NUVL |
S, Open-market sale | 1,000,000 disposed | 97.75 | 97,750,000.00 | Form 4, filing 0001193805-24-001275 | |
| 2024-03-12 |
AdaptHealth Corp. AHCO |
S, Open-market sale | 114,906 disposed | 10.70 | 1,229,494.20 | Form 4, filing 0001193805-24-000360 | |
| 2024-03-11 |
AdaptHealth Corp. AHCO |
S, Open-market sale | 94,567 disposed | 10.92 | 1,032,671.64 | Form 4, filing 0001193805-24-000360 | |
| 2024-03-11 |
AdaptHealth Corp. AHCO |
S, Open-market sale | 88,040 disposed | 11.13 | 979,885.20 | Form 4, filing 0001193805-24-000360 | |
| 2024-03-08 |
AdaptHealth Corp. AHCO |
S, Open-market sale | 47,992 disposed | 10.92 | 524,072.64 | Form 4, filing 0001193805-24-000360 | |
| 2024-03-08 |
AdaptHealth Corp. AHCO |
S, Open-market sale | 4,495 disposed | 11.03 | 49,579.85 | Form 4, filing 0001193805-24-000360 | |
| 2024-02-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 1,430,206 acquired | 8.74 | 12,500,000.44 | Form 4, filing 0001193805-24-000245 | |
| 2024-02-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 1,430,206 acquired | 8.74 | 12,500,000.44 | Form 4, filing 0001193805-24-000245 | |
| 2024-02-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 1,430,205 acquired | 8.74 | 12,499,991.70 | Form 4, filing 0001193805-24-000245 | |
| 2022-11-03 |
Nuvalent, Inc. NUVL |
P, Open-market purchase | 650,000 acquired | 33.50 | 21,775,000.00 | Form 4, filing 0001193805-22-001493 | |
| 2022-09-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,777,777 acquired | 3.15 | 8,749,997.55 | Form 4, filing 0001193805-22-001296 | |
| 2022-09-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,777,777 acquired | 3.15 | 8,749,997.55 | Form 4, filing 0001193805-22-001296 | |
| 2022-09-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,777,777 acquired | 3.15 | 8,749,997.55 | Form 4, filing 0001193805-22-001296 | |
| 2022-09-16 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 2,777,777 acquired | 3.15 | 8,749,997.55 | Form 4, filing 0001193805-22-001296 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 13,132 disposed | 25.29 | 332,108.28 | Form 4, filing 0001193805-22-000932 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 11,868 disposed | 25.29 | 300,141.72 | Form 4, filing 0001193805-22-000932 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 6,909 disposed | 24.47 | 169,063.23 | Form 4, filing 0001193805-22-000932 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 6,243 disposed | 24.47 | 152,766.21 | Form 4, filing 0001193805-22-000932 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 171 disposed | 25.08 | 4,288.68 | Form 4, filing 0001193805-22-000932 | |
| 2022-06-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 155 disposed | 25.08 | 3,887.40 | Form 4, filing 0001193805-22-000932 | |
| 2021-07-09 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 99,325 disposed | 15.81 | 1,570,328.25 | Form 4, filing 0001193805-21-001014 | |
| 2021-07-07 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 6,837 disposed | 15.87 | 108,496.35 | Form 4, filing 0001193805-21-000999 | |
| 2021-07-06 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 49,239 disposed | 16.20 | 797,425.60 | Form 4, filing 0001193805-21-000999 | |
| 2021-07-02 |
Mirum Pharmaceuticals, Inc. MIRM |
S, Open-market sale | 10,599 disposed | 17.01 | 180,299.59 | Form 4, filing 0001193805-21-000999 | |
| 2021-06-30 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 228,571 acquired | 8.75 | 1,999,996.25 | Form 4, filing 0001193805-21-000974 | |
| 2021-06-30 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 228,570 acquired | 8.75 | 1,999,987.50 | Form 4, filing 0001193805-21-000974 | |
| 2021-06-30 |
Larimar Therapeutics, Inc. LRMR |
P, Open-market purchase | 228,569 acquired | 8.75 | 1,999,978.75 | Form 4, filing 0001193805-21-000974 | |
| 2021-06-01 |
Singular Genomics Systems, Inc. OMIC |
P, Open-market purchase | 1,050,000 acquired | 22.00 | 23,100,000.00 | Form 4, filing 0001193805-21-000800 | |
| 2021-06-01 |
Singular Genomics Systems, Inc. OMIC |
P, Open-market purchase | 450,000 acquired | 22.00 | 9,900,000.00 | Form 4, filing 0001193805-21-000800 | |
| 2021-03-30 |
Edgewise Therapeutics, Inc. EWTX |
P, Open-market purchase | 625,000 acquired | 16.00 | 10,000,000.00 | Form 4, filing 0001193805-21-000435 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- P, Open-market purchase
- Open-market purchase
- S, Open-market sale
- Open-market sale
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Deerfield Private Design Fund IV, L.P., insider transactions. Retrieved 2026-08-21 from https://ebomi.com/insider/0001680307
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6